ArticleCPT: pharmacometrics & systems pharmacology2016
Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis.
Article in CPT: pharmacometrics & systems pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Applying a Pharmacometrics-Enabled Machine Learning Analysis to Predict 2-Month Culture Conversion Using Phase 2a Data in a Tuberculosis Clinical Trial.Clinical and translational science · 2026Trial
- Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients.Antimicrobial agents and chemotherapy · 2020Trial
- Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development.Frontiers in pharmacology · 2023Article
- Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development.Frontiers in pharmacology · 2023Article
- Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation ofFrontiers in pharmacology · 2022Review
- Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans.British journal of pharmacology · 2020Article
- Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug Development.Clinical and translational science · 2020Article
- A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis.Journal of pharmacokinetics and pharmacodynamics · 2020Article
- Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis.Open forum infectious diseases · 2020Article
- Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?The Journal of antimicrobial chemotherapy · 2019Article
- Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients.Antimicrobial agents and chemotherapy · 2019Article
- Quantitative assessment of the activity of antituberculosis drugs and regimens.Expert review of anti-infective therapy · 2019Review
- Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin.Clinical pharmacology and therapeutics · 2018Article
- Comparisons of Analysis Methods for Assessment of Pharmacodynamic Interactions Including Design Recommendations.The AAPS journal · 2018Article
- A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations.The Journal of antimicrobial chemotherapy · 2018Article
- An automated sampling importance resampling procedure for estimating parameter uncertainty.Journal of pharmacokinetics and pharmacodynamics · 2017Article
- Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models.CPT: pharmacometrics & systems pharmacology · 2017Article
- Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.The Journal of antimicrobial chemotherapy · 2017Article
- The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model.Journal of pharmacokinetics and pharmacodynamics · 2017Article
- Translational PK/PD of anti-infective therapeutics.Drug discovery today. TechnologiesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is the first clinical implementation of the Multistate Tuberculosis Pharmacometric (MTP) model describing fast-, slow-, and nonmultiplying bacterial states of Mycobacterium tuberculosis. Colony forming unit data from 19 patients treated with rifampicin were analyzed. A previously developed rifampicin population pharmacokinetic (PK) model was linked to the MTP model previously developed using in vitro data. Drug effect was implemented as exposure-response relationships tested at several effect sites, both alone and in combination. All MTP model parameters were fixed to in vitro estimates except Bmax . Drug effect was described by an on/off effect inhibiting growth of fast-multiplying bacteria in addition to linear increase of the stimulation of the death rate of slow- and nonmultiplying bacteria with increasing drug exposure. Clinical trial simulations predicted well three retrospective clinical trials using the final model that confirmed the potential utility of the MTP model in antitubercular drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.